Publications by authors named "Naoki Nagata"

Claim this Profile
F
First Report of Single-Surgeon Single-Incision Laparoscopic Percutaneous Extraperitoneal Closure Using the Senhance Robotic System as Camera Holder for Pediatric Inguinal Hernia.
Daiki Kato, Takahisa Tainaka, Chiyoe Shirota, Satoshi Makita, Katsuhiro Ogawa, Naoki Nagata

Asian J Endosc Surg· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Low Ligation on Bowel Perfusion and Anastomotic Leakage in Minimally Invasive Rectal Cancer Surgery: A Post Hoc Analysis of a Randomized Controlled Trial.
Kei Kimura, Jun Watanabe, Yusuke Suwa, Masanori Kotake, Shingo Noura, Naoki Nagata

Dis Colon Rectum· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Squamous cell carcinoma of the gallbladder with direct invasion to adjacent organs:a case report].
Atsushi Toyofuku, Masaya Bando, Koichi Nakamura, Kohei Yoshida, Yoshinori Inamasu, Naoki Nagata

Nihon Shokakibyo Gakkai Zasshi· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Poorly differentiated hepatocellular carcinoma with sarcomatous change causing intraparenchymal rupture and rapid turnaround: a case report].
Atsushi Toyofuku, Hiroaki Kuroda, Masaya Bando, Koichi Nakamura, Kohei Yoshida, Naoki Nagata

Nihon Shokakibyo Gakkai Zasshi· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First pediatric pelvic surgery with the Senhance® robotic surgical system: A case series.
Daiki Kato, Hiroo Uchida, Chiyoe Shirota, Takahisa Tainaka, Satoshi Makita, Naoki Nagata

Asian J Endosc Surg· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Ryohei Kawabata, Keisho Chin, Daisuke Takahari, Hisashi Hosaka, Osamu Muto, Naoki Nagata

Gastric Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Re-Administration of Anti-EGFR Antibody Drugs for Unresectable Colorectal Cancer-Focusing on Tumor Markers].
Ryota Murayama, Akiko Sakurai, Kohei Yoshida, Yugo Iha, Takehide Tajima, Naoki Nagata

Gan To Kagaku Ryoho· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Jun Watanabe, Hiromichi Maeda, Takeshi Nagasaka, Mitsuru Yokota, Keiji Hirata, Naoki Nagata

Int J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case Report of Primary Unresectable Hilar Cholangiocarcinoma Causing Colonic Obstruction Due to Peritoneal Dissemination.
Atsushi Toyofuku, Hiroaki Kuroda, Kazuma Ito, Akiko Sakurai, Kohei Yoshida, Naoki Nagata

J UOEH· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A Case of Ascending Colon Cancer with Skull Metastasis].
Atsushi Toyofuku, Rina Torii, Masaru Idei, Kazuma Ito, Akiko Sakurai, Naoki Nagata

J UOEH· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive cribriform carcinoma of the breast detected incidentally on computed tomography: A case report.
Yasuhiro Adachi, Takefumi Katsuki, Takakazu Sasaguri, Keiji Hirata, Naoki Nagata

Clin Case Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Two Cases of Synchronous Double Primary Prostate Cancer Accompanying Bone Metastasis and Colon Cancer].
Atsushi Toyofuku, Yugo Iha, Yuki Koreeda, Kohei Yoshida, Aiichiro Higure, Naoki Nagata

J UOEH· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).
Keiichiro Ishibashi, Toru Aoyama, Masahito Kotaka, Hironaga Satake, Yasushi Tsuji, Naoki Nagata

Cancer Chemother Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy.
Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Naoki Nagata

Cancer Chemother Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Hironaga Satake, Takeshi Kato, Koji Oba, Masahito Kotaka, Yoshinori Kagawa, Naoki Nagata

Oncologist· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Naoki Nagata

Cancer Chemother Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials.
Hiromichi Maeda, Shoichi Hazama, Shigeyoshi Iwamoto, Koji Oba, Ryouichi Tsunedomi, Naoki Nagata

Oncol Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer.
Yukio Abe, Yoshifumi Nakayama, Takefumi Katsuki, Yuzuru Inoue, Noritaka Minagawa, Naoki Nagata

Asia Pac J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
Naoki Nagata, Hiromichi Maeda, Keiichiro Ishibashi, Keiji Hirata, Akitaka Makiyama

Med Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study.
Hiromichi Maeda, Naoki Nagata, Takeshi Nagasaka, Koji Oba, Hideyuki Mishima

Oncol Lett· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer.
Shigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, Koji Oba, Naoko Okayama, Naoki Nagata

J Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Yoshinori Munemoto, Mitsuro Kanda, Koji Oba, Ho Min Kim, Hiroyoshi Takemoto, Naoki Nagata

Cancer Chemother Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
Kazuhiro Nishikawa, Toru Aoyama, Mari S Oba, Takaki Yoshikawa, Chu Matsuda, Naoki Nagata

J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
Naoki Nagata, Hideyuki Mishima, Shuichi Kurosawa, Koji Oba, Junichi Sakamoto

Clin Colorectal Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial).
Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, Kenji Doden, Masato Kataoka, Naoki Nagata

Oncol Lett· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis